Molecular mechanisms of resistance to antibiotics in Bartonella bacilliformis

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 6, 2007, Pages 1065-1070

  Biswas, Silpak ^a   Raoult, Didier ^a   Rolain, Jean Marc ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Bioinformatics; Carrion's disease; Disc diffusion assay; Genomic; In vitro selection

Indexed keywords

ANTIBIOTIC AGENT; ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; PHENYLALANINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA 23S; RNA POLYMERASE BETA SUBUNIT; SERINE;

AGAR MEDIUM; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIAL STRAIN; BARTONELLA BACILLIFORMIS; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; GENE AMPLIFICATION; IN VITRO STUDY; MOLECULAR MECHANICS; NONHUMAN;

ANTI-BACTERIAL AGENTS; BARTONELLA BACILLIFORMIS; BARTONELLA INFECTIONS; BASE SEQUENCE; CIPROFLOXACIN; DNA, BACTERIAL; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN;

EID: 34447513153     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm105     Document Type: Article

References (39)

1. Alexander B. A review of bartonellosis in Ecuador and Colombia. Am J Trop Med Hyg 1995; 52: 354-9.
2. Anderson BE, Neuman MA. Bartonella spp. as emerging human pathogens. Clin Microbiol Rev 1997; 10: 203-19.
3. Jacomo V, Kelly PJ, Raoult D. Natural history of Bartonella infections (an exception to Koch's postulate). Clin Diagn Lab Immunol 2002; 9: 8-18.
4. Ihler GM. Bartonella bacilliformis: Dangerous pathogen slowly emerging from deep background. FEMS Microbiol Lett 1996; 144 1-11.
5. Arias-Stella J, Lieberman PH, Erlandson RA. Histology, immuno-chemistry, and ultrastructure of the verruga in Carrion's disease. Am J Surg Pathol 1986; 10: 595-610.
6. Maguina C, Garcia PJ, Gotuzzo E et al. Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis 2001; 33: 772-9.
7. Gray GC, Johnson AA, Thornton SA et al. An epidemic of Oroya fever in the Peruvian Andes. Am J Trop Med Hyg 1990; 42: 215-21.
8. Rolain JM, Brouqui P, Koehler JE et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48: 1921-33.
9. Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: I. Bartonellosis and trench fever. Pediatr Infect Dis J 1997; 16: 2-10.
10. Maguina Vargas C. Bartonellosis o enfermedad de carrion Nuevos aspectos de una vieja enfermedad. Lima, Peru, 1998.
11. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-92.
12. Fluit AC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev 2001; 14: 836-71.
13. Bagel S, Hullen V, Wiedemann B et al. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 1999; 43: 868-75.
14. Minnick MF, Wilson ZR, Smitherman LS et al. gyrA mutations in ciprofloxacin-resistant Bartonella bacilliformis strains obtained in vitro. Antimicrob Agents Chemother 2003; 47: 383-6.
15. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31: 623-31.
16. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001; 45 1-12.
17. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39: 577-85.
18. Canu A, Malbruny B, Coquemont M et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 125-31.
19. Gregory ST, Dahlberg AE. Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA. J Mol Biol 1999; 289: 827-34.
20. Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-50.
21. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc Lung Dis 1998; 79: 3-29.
22. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-60.
23. Katsukawa C, Tamaru A, Miyata Y et al. Characterization of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan. J Appl Microbiol 1997; 83: 634-40.
24. Branger S, Rolain JM, Raoult D. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffensis, and Anaplasma phagocytophilum by real-time PCR. Antimicrob Agents Chemother 2004; 48: 4822-8.
25. Meghari S, Rolain JM, Grau GE et al. Antiangiogenic effect of erythromycin: An in vitro model of Bartonella quintana infection. J Infect Dis 2006; 193: 380-6.
26. Biswas S, Raoult D, Rolain JM. Molecular characterization of resistance to macrolides in Bartonella henselae. Antimicrob Agents Chemother 2006; 50: 3192-3.
27. Cambau E, Sougakoff W, Besson M et al. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 1351.
28. Rodriguez JC, Ruiz M, Climent A et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001; 17: 229-31.
29. Kocagoz T, Hackbarth CJ, Unsal I et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-74.
30. Heisig P, Tschomy R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284-91.
31. Pfister P, Corti N, Hobbie S et al. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A→G. Proc Natl Acad Sci USA 2005; 102 5180-5.
32. Rolain JM, Maurin M, Raoult D. Bactericidal effect of antibiotics on Bartonella and Brucella spp.: Clinical implications. J Antimicrob Chemother 2000; 46: 811-4.
33. Maurin M, Gasquet S, Ducco C et al. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother 1995; 39: 2387-91.
34. Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12: 137-55.
35. Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. J Antimicrob Chemother 1995; 36: 101-8.
36. Rolain JM, Maurin M, Mallet MN et al. Culture and antibiotic susceptibility of Bartonella quintana in human erythrocytes. Antimicrob Agents Chemother 2003; 47: 614-9.
37. Raoult D, Fournier PE, Vandenesch F et al. Outcome and treatment of bartonella endocarditis. Arch Intern Med 2003; 163: 226-30.
38. Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother 2003; 47: 2204-7.
39. Maguina C, Gotuzzo E. Bartonellosis - new and old. Infect Dis Clin North Am 2000; 14: 1-22.